Redeye provides a research update following the Q3 report published by OncoZenge earlier today. The report was largely in line with our expectations, with OPEX of SEK8.9m coming in slightly below our estimate of SEK9.7m and a cash position of SEK24.3m following the completed rights issue. Furthermore, the company stated that recruitment in the pivotal Phase III BEAM-Pain trial has been slower than anticipated, with the trial now targeted for completion as early as possible in 2027. On a positive note, OncoZenge has received several written, non-binding licensing offers for a number of countries and regions. We reiterate our fair value of SEK8 per share.
LÄS MER
